^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 20 insertion

    i
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/25/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-1 • CTLA4
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) (NCT04965090)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    09/30/2021
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON) (NCT04538664)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/13/2020
    Primary completion :
    05/03/2023
    Completion :
    01/31/2026
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)
    Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) (NCT02609776)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/24/2016
    Primary completion :
    01/31/2024
    Completion :
    06/30/2025
    ALK • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) (NCT05498428)
    Phase 2
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    11/11/2022
    Primary completion :
    10/31/2025
    Completion :
    08/05/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (CHRYSALIS-2) (NCT04077463)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/04/2019
    Primary completion :
    02/03/2025
    Completion :
    06/03/2026
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) (NCT04606381)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/10/2020
    Primary completion :
    07/11/2024
    Completion :
    10/21/2025
    MET
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
    Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (UCLA l-08) (NCT04285671)
    Phase 1/2
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/29/2021
    Primary completion :
    12/02/2025
    Completion :
    12/02/2026
    HER-2 • AXL
    |
    EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/11/2016
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (NCT05559645)
    Phase N/A
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    11/18/2021
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    sunvozertinib (DZD9008)
    Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    02/21/2023
    Primary completion :
    06/30/2029
    Completion :
    06/30/2029
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (NCI-2017-00831) (NCT03066206)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • HER-2
    |
    EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation
    |
    Pozenveo (poziotinib)
    A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) (NCT05668988)
    Phase 3
    Dizal Pharmaceuticals
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    12/13/2022
    Primary completion :
    02/28/2026
    Completion :
    10/31/2027
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    carboplatin • pemetrexed • sunvozertinib (DZD9008)
    TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (EXCLAIM-2) (NCT04129502)
    Phase 3
    Takeda
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    01/10/2020
    Primary completion :
    12/30/2024
    Completion :
    12/30/2024
    HER-2
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)
    Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (WK-KONG1) (NCT03974022)
    Phase 1/2
    Dizal Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    07/09/2019
    Primary completion :
    07/01/2024
    Completion :
    07/01/2025
    EGFR • HER-2
    |
    EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    sunvozertinib (DZD9008)
    Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (ORIC-114-01) (NCT05315700)
    Phase 1/2
    ORIC Pharmaceuticals
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/10/2022
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    EGFR • HER-2
    |
    EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
    |
    carboplatin • pemetrexed • ORIC-114
    First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer (FIOL) (NCT03804580)
    Phase 2
    Vestre Viken Hospital Trust
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    12/01/2018
    Primary completion :
    06/01/2025
    Completion :
    12/31/2025
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 18 mutation
    |
    Tagrisso (osimertinib)
    A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (NCT06046495)
    Phase 1
    Avistone Biotechnology Co., Ltd.
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    11/29/2023
    Primary completion :
    02/09/2028
    Completion :
    02/09/2028
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PLB1004
    First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (NCT06043817)
    Phase 1/2
    Scorpion Therapeutics, Inc.
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    09/26/2023
    Primary completion :
    06/01/2027
    Completion :
    06/01/2028
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    STX-721
    A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer (NCT03807778)
    Phase 1
    Takeda
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    02/04/2019
    Primary completion :
    11/08/2021
    Completion :
    03/31/2025
    EGFR • HER-2
    |
    EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation
    |
    Exkivity (mobocertinib)
    A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (NCT05704634)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    08/18/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2028
    STK11
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)
    Osimertinib for NSCLC With Uncommon EGFR Mutations (UNICORN) (NCT05421936)
    Phase N/A
    Sheba Medical Center
    Suspended
    Last update posted :
    11/22/2023
    Initiation :
    09/27/2020
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (EXCLAIM) (NCT02716116)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    10/18/2023
    Initiation :
    06/16/2016
    Primary completion :
    03/28/2025
    Completion :
    03/28/2025
    HER-2
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (AFACET) (NCT03727724)
    Phase 2
    The Netherlands Cancer Institute
    Completed
    Last update posted :
    10/18/2023
    Initiation :
    12/04/2018
    Primary completion :
    09/06/2022
    Completion :
    09/06/2022
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer (NCT05517083)
    Phase N/A
    Pusan National University Hospital
    Recruiting
    Last update posted :
    10/17/2023
    Initiation :
    09/01/2022
    Primary completion :
    12/31/2023
    Completion :
    06/30/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR G719X • EGFR S768I
    A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations (KCSG-LU15-09) (NCT03434418)
    Phase 2
    Duke University
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    06/30/2018
    Primary completion :
    10/12/2022
    Completion :
    10/12/2022
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer (NCT05045404)
    Phase 2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    09/13/2023
    Initiation :
    06/16/2021
    Primary completion :
    02/02/2023
    Completion :
    02/02/2023
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Cyramza (ramucirumab) • Pozenveo (poziotinib)
    Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001) (NCT06029816)
    Phase 2
    Convalife (Shanghai) Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/08/2023
    Initiation :
    11/20/2023
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation
    |
    Nerlynx (neratinib)
    A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion (ermEX-20) (NCT05419700)
    Phase N/A
    Takeda
    Completed
    Last update posted :
    09/06/2023
    Initiation :
    08/05/2022
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (NCT05940116)
    Phase 1
    Hansoh BioMedical R&D Company
    Not yet recruiting
    Last update posted :
    07/12/2023
    Initiation :
    07/20/2023
    Primary completion :
    07/30/2025
    Completion :
    07/30/2027
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    PM1080
    A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer (NCT05769764)
    Phase N/A
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    04/10/2023
    Initiation :
    12/19/2022
    Primary completion :
    04/06/2023
    Completion :
    04/06/2023
    KRAS • ALK • ERBB3
    |
    KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (NCT05767892)
    Phase 3
    Suzhou Puhe Pharmaceutical Technology Co., LTD
    Not yet recruiting
    Last update posted :
    04/05/2023
    Initiation :
    05/01/2023
    Primary completion :
    07/30/2025
    Completion :
    12/31/2026
    HER-2
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • PH001
    Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer (NCT04974879)
    Phase 2
    Qingdao Central Hospital
    Recruiting
    Last update posted :
    03/29/2023
    Initiation :
    07/01/2021
    Primary completion :
    07/31/2024
    Completion :
    12/31/2024
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib)
    DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation (NCT05712902)
    Phase 2
    Dizal Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/06/2023
    Initiation :
    07/19/2021
    Primary completion :
    10/17/2022
    Completion :
    05/06/2024
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    sunvozertinib (DZD9008)
    Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion (NCT05466149)
    Phase 2
    Allist Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    02/01/2023
    Initiation :
    09/27/2022
    Primary completion :
    04/01/2024
    Completion :
    08/01/2026
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Ivesa (firmonertinib)
    Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR) (NCT04858958)
    Phase 1
    Allist Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    01/18/2023
    Initiation :
    08/10/2020
    Primary completion :
    03/01/2023
    Completion :
    12/01/2023
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR positive
    |
    Ivesa (firmonertinib)